Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update

Synaptogenix, Inc. (NASDAQ:SNPX) was the recipient of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 21,800 shares, a decrease of 26.8% from the February 13th total of 29,800 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average trading volume of 15,000 shares, the days-to-cover ratio is currently 1.5 days.

Institutional Trading of Synaptogenix

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC acquired a new position in shares of Synaptogenix, Inc. (NASDAQ:SNPX) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.80% of Synaptogenix as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 10.34% of the company’s stock.

Synaptogenix Trading Down 6.2 %

SNPX traded down $0.18 during midday trading on Friday, hitting $2.72. The company had a trading volume of 4,473 shares, compared to its average volume of 12,095. Synaptogenix has a twelve month low of $2.32 and a twelve month high of $6.22. The firm’s 50-day simple moving average is $3.12 and its 200-day simple moving average is $3.08.

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.